Relief Therapeutics Holding AG (RLFTF)

[tcm55]

GEM thru RLF shareholders paid for the CT and the RLF-100 patent for formulations of VIP which is at Relief, and it was managed some by NRX as agreed in part of the revenue share agreement and to bring DrJJ supposed expertise into managing the medical side. GEM also financed NRX-100/101 pre COVID but that trial was delayed.
Pissing match and finger pointing continues due to endpoint / WHO unrealistic initial goals. Early Data for the EAP near death patients was lost in the CT values for the moderate CT and confusing endpoints.
Pathetic managing of data releases did not help. What company gets blame or benefits and how will Nasdaq Moves happen is my concern now. NRXP? RLFAC? Combo? FUBAR????!!!????
I Guess GEM is pissed about This AFU situation and institutional investors NOT involved. I was...GLTA...